<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.
Olivier van NotWilleke A M BlokxAlfons J M van den EertweghMelissa M de MezaJohn B A G HaanenChristian U BlankMaureen J B AartsFranchette W P J van den BerkmortelJan Willem B de GrootGeke A P HospersEllen H W KapiteijnDjura PiersmaRozemarijn S van RijnMarion A Stevense-den BoerAstrid A M van der VeldtMarye J Boers-SonderenAnne M L JansenMichel W J M WoutersKarijn P M SuijkerbuijkPublished in: JCO precision oncology (2022)
Ipilimumab-nivolumab-treated patients with <i>BRAF</i>-mutant melanoma display improved PFS and OS compared with patients with <i>NRAS</i>-mutant and double wild-type melanoma. <i>BRAF</i> mutation status is a factor to consider while choosing between mono and dual checkpoint inhibition in advanced melanoma.